ロード中...
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer
Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular molecules involved in the modulation of angiogenesis and lymphangiogenesis: vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, and platelet-derived growth factor rece...
保存先:
| 出版年: | Onco Targets Ther |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5079697/ https://ncbi.nlm.nih.gov/pubmed/27799794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S84625 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|